Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non Operating Income (2020 - 2025)

Barinthus Biotherapeutics' Non Operating Income history spans 6 years, with the latest figure at -$104000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 103.71% year-over-year to -$104000.0; the TTM value through Dec 2025 reached $1.9 million, down 55.55%, while the annual FY2025 figure was $16000.0, 99.76% down from the prior year.
  • Non Operating Income reached -$104000.0 in Q4 2025 per BRNS's latest filing, up from -$275000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.8 million in Q4 2024 to a low of -$9.3 million in Q1 2021.
  • Average Non Operating Income over 5 years is $331850.0, with a median of $323000.0 recorded in 2021.
  • Peak YoY movement for Non Operating Income: crashed 1429.37% in 2021, then skyrocketed 10765.0% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $335000.0 in 2021, then surged by 470.45% to $1.9 million in 2022, then plummeted by 59.5% to $774000.0 in 2023, then skyrocketed by 262.02% to $2.8 million in 2024, then plummeted by 103.71% to -$104000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Non Operating Income are -$104000.0 (Q4 2025), -$275000.0 (Q3 2025), and $2.2 million (Q2 2025).